For demonstrating a commitment to fostering greater equity, diversity, and inclusion through mentoring and broadening the talent pool in health care settings.
Dedicated to gender equality and the empowerment of women in medicine, Women As One was founded by Dr. Roxana Mehran and Dr. Marie-Claude Morice in 2019. The organization builds a more inclusive, diverse, and equitable workforce in medicine by connecting female physicians to funding, training, and professional opportunities.
Internationally renowned for her work in clinical trials with complex data analyses and outcomes research, Dr. Mehran is a professor of medicine and director of interventional cardiovascular research and clinical trials at The Zena and Michael A. Weiner Cardiovascular Institute at Icahn School of Medicine at Mount Sinai, in New York.
A program director of CRF's Transcatheter Cardiovascular Therapeutics (TCT), Dr. Mehran also is a co-founder and program chair of SCAI's Women in Innovations, a global initiative to create and strengthen opportunities for research, education, and professional advancement among female interventional cardiologists.
For demonstrating leadership, effecting positive change, adopting innovative methods to improve access to care, or making an exceptional impact on health care delivery and patient quality of life.
A leading voice in the effort to reduce health disparities, Dr. Foluso Fakorede practices interventional cardiology in central Mississippi, where he founded Cardiovascular Solutions of Central Mississippi to provide quality health care in a region where it is often lacking. As the co-chair of the PAD Initiative of the Association of Black Cardiologists, Dr. Fakorede devotes himself to reducing peripheral arterial disease (PAD) and promoting limb-salvage. He has testified on Capitol Hill about the PAD epidemic and his Sprint to Zero Amputation Campaign, which promotes policies to stop unnecessary amputation. As a result of Dr. Fakorede's care and efforts, he has reduced amputations by 88% over a three-year period in the Mississippi Delta.
For an exceptional leader who demonstrates unwavering commitment to perform at an elevated standard of excellence.
Starting as a cardiovascular technologist more than 30 years ago, Sam Conaway leveraged his cath-lab experience to become a passionate leader in the medical device industry. Sam is currently the president of U.S. cardiology sales at Boston Scientific and a member of the executive leadership team, where he provides strategic direction for the interventional cardiology division. He was instrumental in establishing Boston Scientific’s prominent position in complex PCI, LAAC, and structural heart valves. Under Sam’s authentic leadership and ability to imagine the future, the company has successfully launched many new products, thereby helping thousands of patients. As chairman of Close the Gap, Boston Scientific’s health equity program, Sam works relentlessly toward ensuring that all patients — regardless of gender, age, race, ethnicity, socioeconomic status, or sexual orientation — understand their medical conditions and have access to therapies to help them live better lives.
Lungpacer Medical is a clinical stage medical device company pioneering a diaphragm pacing therapy system for critically ill patients who require mechanical ventilation. This unique device has the potential to help mechanically ventilated patients return to natural breathing more quickly by improving diaphragm strength and lung function.
Doug Evans is an accomplished medical device executive, business leader, and strategist with 30 years of industry, public, and private company experience. A professional engineer, Doug is president and chief executive officer of Lungpacer Medical Inc. and is a serial innovator of first-of-kind products. He holds more than 200 patents covering dozens of devices used by more than 15 million patients worldwide and generating greater than $4 billion in end-user sales.
Doug is the co-founder of Cure4Cam Childhood Cancer Foundation, which seeks to raise community awareness about childhood cancers and supports the development of new and more humane therapies for children.